

EXPANDED  
brochure



**eurobio**  
SCIENTIFIC

An advanced gene expression test for predicting the risk of distant recurrence in early-stage primary breast cancer.

*Risk of Breast Cancer Recurrence • Benefits of  
Chemotherapy • Suitability for Extended  
Endocrine Therapy*

Partial  
**MEDICARE  
REBATE**  
*Available*



*Only available at*

AUSTRALIAN

 **Clinicallabs**



Personalised medicine helps guide  
ER+, HER2-, N0 and N+, pre or post-menopausal breast  
cancer treatment decisions



**EndoPredict®**  
One Test – Three Clinical Answers

The **ONLY** test that answers the following  
three important clinical questions...

Can chemotherapy  
be avoided?

(Risk at 10 years<sup>1</sup>)

What is the absolute  
benefit from  
chemotherapy?

(Chemotherapy benefit<sup>2</sup>)

Can the extension of  
endocrine therapy  
be avoided?


(Risk between 5 and 15 years<sup>3</sup>)

... to optimise treatment for your breast  
cancer patients

EndoPredict is designed for women with ER+, HER2- primary breast cancer  
(node-negative or node-positive (micrometastases, 1-3 nodes), pre- or postmenopausal)

## One Test – Three Clinical Answers

EndoPredict is a gene expression assay for patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) early-stage breast cancer who are lymph node negative or positive (N0, N+). The second generation test combines a molecular score with tumour size and nodal status to provide more prognostic power than first generation tests.



In the result report the individual risk, either low or high, is clearly indicated for each patient. In addition the risk of early and late distant recurrence with 5 years of adjuvant endocrine therapy alone and the estimated absolute benefit of chemotherapy are determined.

EndoPredict provides highly important and clear information for different stages of treatment planning.

### **Initial treatment planning:**

10-year risk of recurrence for patients with node-negative or node-positive disease<sup>1</sup> and estimated absolute chemotherapy benefit at 10 years based on modern treatment regimens.<sup>2</sup>

### **Long-term treatment planning:**

Breast cancer recurrence risk out to 15 years.<sup>3</sup>

Patients at low risk of distant recurrence are usually treated initially without chemotherapy. Under endocrine therapy alone, more than 95% of EndoPredict low-risk patients do not experience a distant recurrence, even more than 10 years after diagnosis.<sup>1</sup>

Compared to risk stratification using clinical parameters or other gene expression tests, EndoPredict identifies the largest group of women with breast cancer at low risk (<10% chance of distant recurrence in 10 years) who might safely avoid chemotherapy.<sup>4,5,6</sup>

For even more treatment confidence, EndoPredict predicts the individual absolute chemotherapy benefit based on modern treatment regimens.<sup>2</sup>

In addition EndoPredict can support long-term treatment planning. Some patients can benefit from prolonged endocrine therapy up to ten years, but other patients can avoid this additional treatment and be safely treated with only 5 years of endocrine therapy.


EndoPredict is the only test that provides your patient's individual risk of breast cancer late distant recurrence within years 5-15<sup>3</sup> to help in deciding whether your patient can avoid extended endocrine therapy.

EndoPredict is the only prognostic test that can help in deciding whether your patient can safely avoid chemotherapy, how beneficial chemotherapy would be, and whether your patient can avoid extended endocrine therapy.

## Measures 8 Genes related to Early and Late Recurrence

**Endopredict** was developed using consistent criteria for patients during training and independent validation studies on 10 year outcome data. ER+/HER2- breast cancer, both N0 and N+.

The **Endopredict** algorithm was generated in a large training set of 964 ER+/HER2- breast cancer samples.<sup>1</sup>




Gene selection process for 12-Genes Molecular Score

Consistent study cohorts for training and validation

	Gene	Assigned biological processes
Proliferation associated Genes	UBE2C	Protein degradation, cell division
	BIRC5	Anti-apoptosis, cell division, cytokinesis, chromosome localization
	DHCR7	Cholesterol biosynthesis
Hormone Receptor associated Genes	STC2	Cell-to-cell communication
	AZGP1	Cell adhesion
	IL6ST	Various signal transduction pathways, cell proliferation, T cell proliferation
	RBBP8	DNA repair
	MGP	Transcriptional regulation

Genes and assigned biological processes



Variable	0-5 years HR (95% CI)	P-value	>5 years HR (95% CI)	P-value
PROLIFERATION	1.60 (1.33-1.92)	<0.001	1.19 (0.85-1.67)	0.298
ER SIGNALING	0.89 (0.75-1.06)	0.204	0.61 (0.46-0.81)	<0.001

A multivariate analysis of the contribution of variables to predict early and late distant recurrence showed proliferation genes provide important additional prognostic information within the first five years, while ER-associated genes are critical to predict late recurrences.<sup>7</sup>

Genes for early and late recurrence<sup>7</sup>

Proliferation and hormone receptor related genes for **early and late recurrence**


EndoPredict measures the activity of eight genes relevant to the course of disease (BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP, STC2). Inclusion of proliferation and hormone receptor related genes contributes to accurate assessment of early and late recurrence risk.<sup>1,7</sup>

These eight genes are compared against three normalization genes (OAZ1, CALM2, RPL37A) and one control gene (HBB). Based on the activity of the genes, the **12-Genes Molecular Score** is calculated using a mathematical algorithm and reported on a scale of 0 to 15.


# Combines Gene Expression and Clinical-Pathological Factors

The final EndoPredict result, the **EPclin Risk Score**, is calculated combining the 12-Gene Molecular Score with clinical pathological prognostic factors (tumour size and lymph node status) as assessed by the pathologist. This makes EndoPredict a second generation gene expression test and a more powerful predictor of prognosis.

The EPclin Risk Score is reported on a scale of 1 to 6. The value of 3.32867 is associated with 10% risk of breast cancer recurrence within 10 years. Values below 3.32867 are associated with low risk and values above or equal to 3.32867 with high risk.



EndoPredict provides a clear classification into **high risk** and a **low risk**




*Prognostic power according to the c-index in comparison to prognostic factors*

The EPclin Risk Score alone is a more powerful predictor of the prognosis than combinations of all classical prognostic factors.<sup>1</sup>

As a second generation gene expression test, EndoPredict is a more powerful predictor of prognosis than first generation assays. Prognostic power providing results you can trust.

**Second generation gene expression test for more prognostic power**



*Prognostic power of gene expression assays*



# Clearly Structured Result Report

Result Report

Created by: EndoPredict Report Generator®

CE

EndoPredict®

Sample Name:

Sample Bb

Note:

Report Created:

2019-02-08 11:11 AM (CET)

12-GENE MOLECULAR SCORE:  
(Range 0-15)

4.9

TUMOR SIZE:

pT1ab (≤1cm)

NODAL STATUS:

1 to 3 positive lymph nodes (incl. pN1mic)

RESULT

EPclin RISK SCORE

3.0

EPclin RISK CLASS

LOW

EndoPredict® is a gene expression assay for patients with ER-positive, HER2-negative early-stage breast cancer. From this genomic analysis, a 12-Gene Molecular Score is assigned. This score, combined with tumor size and nodal status, contributes to the EPclin Risk Score, from which the risks of distant recurrence (10-year and 5 to 15-years) with 5 years of adjuvant endocrine therapy alone and the estimated absolute benefit of chemotherapy (at 10 years) are determined. The EPclin Risk Class refers to the risk of distant recurrence with 5 years of adjuvant endocrine therapy alone.

INITIAL Treatment Planning

LIKELIHOOD OF DISTANT RECURRENCE WITHIN YEARS 0-10  
For patients treated with 5 years of endocrine therapy alone

7%

ABSOLUTE CHEMOTHERAPY BENEFIT AT 10 YEARS

2%

LONG-TERM Treatment Planning

LIKELIHOOD OF LATE DISTANT RECURRENCE WITHIN YEARS 5-15  
For patients with no recurrence after 5 years of endocrine therapy alone

6%

AUTHORIZED SIGNATURE

myriad

Myriad, the Myriad logo, EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. ©2018, Myriad Genetics GmbH. EPRG V4.1.1-SNAPSHOT

page 1 of 5

EndoPredict result report front page (low risk)

An overview of the three clinical answers given by Endopredict is organized by treatment planning stage.

## Initial treatment planning

1. Risk at 10 years - Can chemotherapy be avoided?
2. Chemotherapy benefit - What is the absolute benefit from chemotherapy?

## Long-term treatment planning

3. Risk between 5 and 15 years - Can the extension of endocrine therapy be avoided?

The EndoPredict Result Report documents the molecular data and the established prognostic factors of tumour size and lymph node status.

Using a mathematical algorithm, the 12-gene molecular score is combined with the clinical data. This results in the patient's individual **EPclin Risk Score** and subsequent classification as "low risk" or "high risk".

Result Report

Created by: EndoPredict Report Generator®

CE

EndoPredict®

Sample Name:

Sample Aa

Note:

Report Created:

2019-02-08 10:55 AM (CET)

12-GENE MOLECULAR SCORE:  
(Range 0-15)

10.1

TUMOR SIZE:

pT1c (>1cm but ≤2cm)

NODAL STATUS:

1 to 3 positive lymph nodes (incl. pN1mic)

RESULT

EPclin RISK SCORE

4.8

EPclin RISK CLASS

HIGH

EndoPredict® is a gene expression assay for patients with ER-positive, HER2-negative early-stage breast cancer. From this genomic analysis, a 12-Gene Molecular Score is assigned. This score, combined with tumor size and nodal status, contributes to the EPclin Risk Score, from which the risks of distant recurrence (10-year and 5 to 15-years) with 5 years of adjuvant endocrine therapy alone and the estimated absolute benefit of chemotherapy (at 10 years) are determined. The EPclin Risk Class refers to the risk of distant recurrence with 5 years of adjuvant endocrine therapy alone.

INITIAL Treatment Planning

LIKELIHOOD OF DISTANT RECURRENCE WITHIN YEARS 0-10  
For patients treated with 5 years of endocrine therapy alone

36%

ABSOLUTE CHEMOTHERAPY BENEFIT AT 10 YEARS

17%

LONG-TERM Treatment Planning

LIKELIHOOD OF LATE DISTANT RECURRENCE WITHIN YEARS 5-15  
For patients with no recurrence after 5 years of endocrine therapy alone

28%

AUTHORIZED SIGNATURE

myriad

Myriad, the Myriad logo, EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. ©2018, Myriad Genetics GmbH. EPRG V4.1.1-SNAPSHOT



page 1 of 5

EndoPredict result report front page (high risk)

Information is summarised by treatment planning stage

# Can chemotherapy be avoided?

This information helps you to identify your patients with a low risk of recurrence who might safely avoid chemotherapy.

[illegible]

# What is the benefit from chemotherapy?

The second graph in the report illustrates the absolute chemotherapy benefit based on whether the patient receives endocrine therapy alone or endocrine plus chemotherapy.



This helps your patient to make a confident chemotherapy treatment decision.

EndoPredict result report third page (low and high risk)

# Can the extension of endocrine therapy be avoided?

The third graph on the report illustrates your patient's risk of recurrence within years 5-15 after diagnosis.\*

This information guides treatment decisions regarding endocrine therapy beyond 5 years.



EndoPredict result report fourth page (low and high risk)

\*5-15 year risk is based on treatment with 5 years of ET only – no chemo. The result assumes the patient has not recurred by 5 years.

# Independently Validated for Robust Prognostic Results

	Trial	# of patients	Breast cancer sub-type	Nodal Status	Treatment	10-year distant metastasis rate in low-risk group
Training	Multicenter <sup>1</sup>	964	ER+/HER2-	N0, N+	E	7%
Validation I	ABCSG-6 <sup>1</sup>	378	ER+/HER2-	N0, N+	E	4%
Validation II	ABCSG-8 <sup>1</sup>	1,324	ER+/HER2-	N0, N+	E	4%
Validation III	GEICAM/9906 <sup>8</sup>	555	ER+/HER2-	N+	E + CT	0%
Validation IV	TransATAC <sup>5</sup>	928	ER+/HER2-	N0, N+	E	5.8%

## Patients in training and validation studies

- Breast cancer subtype ER+, HER2-
- Nodal status N0 or N+
- Adjuvant treatment 5 years of endocrine therapy (not extended)


EndoPredict training and validation studies

EndoPredict was developed using consistent criteria for patients during training and independent validation studies - ER+, HER2- patients, both node-negative (N0) and node-positive (N+). These "clean" cohorts are one reason for the test's stronger performance compared to tests that included HER2+ patients in their training cohorts. The score and the cutoff value is consistent in all studies and has never changed.

The patients in the ABCSG6, ABCSG8 and TransATAC studies were treated with endocrine therapy alone. The prognostic value of EndoPredict under chemotherapy was demonstrated by the GEICAM/9906 study. All patients received only 5 years of hormone therapy.

Validated in four prospective-retrospective studies<sup>1, 2, 3, 4, 5, 8</sup> providing **level 1 evidence**

Consistently identifies a large low risk group with a recurrence risk of less than 10%



Analysis of ER+, HER2-, N+ and N0 patients from ABCSG-6, ABCSG-8 and TransATAC<sup>1,5</sup>




# Identifies Clear Risk Groups in Different Subgroups

EndoPredict supplies additional prognostic information to supplement common prognostic factors such as nodal status, tumour grade or Ki67. This has been demonstrated in four validation studies.



EndoPredict identifies a large percentage of low risk patients (average of 6% recurrence) <sup>1, 3, 5, 6</sup>

- More than 70% of N0 patients
- Up to 30% of N+ patients

Risk assessment  
independent of  
nodal status



Analysis of ER+, HER2- patients from both ABCSG-6 and ABCSG-8 <sup>7</sup>



EndoPredict identifies high and low risk patients independent from tumour grade.<sup>4</sup>

- 22% high risk in grade 1 patients
- 60% low risk in grade 2 patients
- 19% low risk in grade 3 patients

Risk assessment  
independent of  
grading

Analysis of ER+, HER2- patients from both ABCSG-6 and ABCSG-8 <sup>4</sup>





## Significantly increases the low risk group

More patients  
can safely forgo  
chemotherapy

Patients at low risk of recurrence do not always require chemotherapy.


Based on previous guidelines that did not yet include gene expression tests, only a few patients could be clearly identified as low risk. Depending on the guideline used, only 6%-19% of patients were classified as low risk in the ABCSG-6&8 study cohorts.

With the additional information supplied by EndoPredict, 63% of patients were categorized as low risk. This means that – based on the EndoPredict test result – many more patients might optimally be treated without chemotherapy.<sup>4</sup>



Kaplan-Meier curve for recurrence free survival from (A) National Comprehensive Cancer Center Network (NCCN) guideline (2007), (B) German S3 Guidelines (2008), (C) St. Gallen Consensus (2011) and (D) EPclin risk groups.<sup>4</sup>

## Divides S3 Intermediate Risk Group in Low- and High-Risk <sup>4</sup>



A patient categorized as intermediate risk from the guidelines has an unclear treatment pathway. With EndoPredict, this intermediate risk group can be divided into a low-risk and a high-risk group.

The much larger EndoPredict low risk group shows a comparable risk of distant metastasis to the group defined as low risk by the guideline. <sup>4</sup>

The clear risk assessment for a period of more than ten years provides greater long-term therapeutic confidence for patients and physicians.

Current guidelines therefore recommend using gene expression analyses in unclear cases (NCCN, ASCO, AGO, ESMO, St. Gallen, EGTM and AJCC).

## Shows Absolute and Relative Benefit of Chemotherapy

EndoPredict predicts chemotherapy benefit in women with ER-positive, HER2-negative disease. Chemobenefit was validated in a large study with over 3,700 patients with ER+, HER2- breast cancer.<sup>2</sup> 2,630 patients were treated with 5 years of endocrine therapy alone and 1,116 patients were treated with endocrine plus chemotherapy with modern (taxane and/or anthracycline-containing) treatment regimens.


EPclin Risk Score		1	2	3	3.3	4	5	6
10 year risk for DRFI	ET alone	1.0% (0.6-1.4)	2.8% (2.1-3.5)	7.6% (6.4-8.8)	10.2% (8.8-11.6)	19.8% (17.6-22.0)	46.1% (40.2-51.4)	82.2% (72.1-88.6)
	ET + C	1.1% (0.5-1.7)	2.5% (1.5-3.5)	5.7% (4.1-7.2)	7.2% (5.4-8.9)	12.4% (10.1-14.6)	25.8% (22.0-29.5)	49.2% (40.5-56.7)
Absolute benefit		-0.1%	0.3%	1.9%	3.0%	7.4%	20.3%	33.0%
Relative benefit		-0.1	0.11	0.25	0.29	0.37	0.44	0.40

Prediction of absolute and relative chemo benefit

In patients with low EPclin Risk Scores, no differences in 10 year risks were observed between endocrine treatment alone and endocrine treatment plus chemotherapy.

Patients with a low risk EndoPredict result did not benefit from the addition of chemotherapy.

Patients with a high risk EndoPredict result had a stronger benefit from chemotherapy. This benefit was more than proportional.




10-year risks by EPclin Risk Score for endocrine treatment (ET) vs. endocrine treatment plus chemotherapy (ET+C)<sup>2</sup>

For an EPclin score of 5.0, women receiving ET alone had a 10-year DRFI risk of 46.1% compared to 25.8% for women who received ET+C.

Personalised absolute  
chemotherapy  
benefit for confident  
treatment decisions

## Provides Recurrence Risk out to 15 years



Risk of breast cancer death after initial diagnosis<sup>9</sup>

EndoPredict is the only prognostic test that successfully predicts risk of early (0-10 years) and late (5-15 years) recurrence for patients with node-negative and node-positive disease.<sup>3</sup>


Late recurrence risk was validated in over 1,300 ER+, HER2- patients. Analyses were performed for the overall cohort, by nodal status, and for patients who were distant recurrence-free at year 5 (late recurrence).

EndoPredict low-risk patients had a consistent low risk of recurrence in years 0-10 and 5-15. The results for the late distant recurrence period (5-15 years) indicate that EPclin Risk Score is informative for selecting patients who may safely forgo extended endocrine therapy.

Guides treatment decisions regarding extended endocrine therapy


After 5 years of endocrine therapy, breast cancer recurrences in ER+ tumours continue to occur steadily up to 20 years after diagnosis. Of those patients with ER+ breast cancer who experience recurrent disease, more than 50% occur after 5 years.<sup>9,10</sup>

Therefore assessment of risk out to 10 or 15 years is important to identify the subgroup of patients who may benefit from extended endocrine therapy beyond 5 years.



Numbers at risk by EPclin risk group

1066	1058	1042	1028	1009	897	769	729	677	574	458	345	223	130	73	31
636	619	601	566	539	489	419	387	354	299	244	182	129	74	47	22



Numbers at risk by EPclin risk group

897	769	729	677	574	458	345	223	130	73	31
489	419	387	354	299	244	182	129	74	47	22

Kaplan-Meier curves of estimated DRFR<sup>3</sup>



## Fast and Reliable

EndoPredict is performed on FFPE tumour tissue from biopsy<sup>11</sup> or surgical specimens<sup>13</sup> from patients who have not received systemic endocrine therapy and/or chemotherapy.

Once the sample has been sent to the laboratory, results are usually available within 1 week.

### SCREENING

- Palpatory findings
- Mammography

### CLINICAL DIAGNOSIS

- Biopsy
- Imaging

### PATHOLOGICAL DIAGNOSIS

- ER, PR, and HER2 status
- Other parameters

### SURGERY

- Tumour size
- Nodal status

### ADJUVANT THERAPY DECISION

- Endocrine therapy
- Chemotherapy if necessary

### PATIENT JOURNEY

### EndoPredict

When performed on a surgical sample, the 12-gene molecular score and the **EPclin Risk Score** are provided in the test report.

If **EndoPredict** is performed on a biopsy specimen, information on surgical tumour size and nodal status can be added after surgery to calculate **EPclin Risk Score**, if the patient was not treated with systemic therapy before the surgery.

Use of EndoPredict during clinical course

## Results within 1 week for fast therapy decisions


An EndoPredict assay takes less than 8 hours in the normal operation of a molecular pathology laboratory. Only a small section of the tumour block (10µm) is required. The tumour content of the tissue sample must be at least 30%. The subsequent RNA extraction is followed by reverse transcription (transcription of RNA into the corresponding cDNA sequence) and quantitative PCR. The gene expression values of all the relevant genes are determined, and the 12-Gene Molecular Score is calculated.

Analysis and quality assurance remain in the hands of the local pathologists.

EndoPredict consistently delivers the same quality of results, regardless of the pathological institute conducting the assay, as has been demonstrated in round-robin testing.<sup>12,13</sup>

Implementing this procedure at a new site requires 2 days of installation and qualification.

This process guarantees the consistent reliability of the EndoPredict result, regardless of the laboratory conducting the assay.



Consistent results and correlations achieved in 15 sites with local implementation

## Proven in Practice

Decision impact studies conducted at different centers documented how EndoPredict results affect the treatment decision in clinical practice.<sup>14, 15, 16, 17, 18</sup>

The treatment plan of each participating patient was discussed before and after release of the EndoPredict result. In the first three mentioned studies in 25.4%, 28.4% and 38% of cases, the treatment decision in favor of chemotherapy was reversed, and the patient was advised to receive endocrine therapy alone. In 12.3%, 7.5% and 5% of cases, chemotherapy was recommended to avoid undertreatment.

Leads to substantial  
change in  
chemotherapy  
decision

Changes in therapy aligned with test result.

Country	Germany	France	Germany	UK	Mexico
Institution	Charité Berlin	Centre Jean Perrin Clermont-Ferrand	Technical University Munich	University of Sussex Brighton	National Institute of Cancerology Monterrey
Publication/ Conference	PlosOne 2013	SABCS 2016	PlosOne 2017	Psycho Oncology 2018	SABCS 2018
First author	Mueller et al. <sup>14</sup>	Penault-Llorca et al. <sup>15</sup>	Ettl et al. <sup>16</sup>	Fallowfield et al. <sup>17</sup>	Villarreal-Garza al. <sup>18</sup>
# patients	167	201	395	149	91
EPclin low risk	46%	67%	63%	50%	46%
EPclin high risk	54%	33%	37%	50%	54%
N0	62%	91%	77%	67%	72%
N+	38%	9%	23%	33%	28%
Change of therapy recommendation	37.7%	35.8%	43.0%	36.9%	17.0%
Net change CT	-13.1%	-20.9%	-33.0%	+0.7%	-10.53%

.....  
Decision Impact Studies with EndoPredict


## Low Risk Results you can Trust

Decisions on the use of adjuvant chemotherapy in ER+, HER2- primary breast cancer are guided by the risk of distant recurrence.

EndoPredict and Oncotype DX® are prognostic gene expression tests used for estimating distant recurrence risk. EndoPredict provides prognostic information from a molecular signature combined with tumour size and nodal status (EPclin Risk Score). Oncotype DX provides prognostic information from a molecular signature only (Recurrence Score RS).


The classification by EndoPredict aligns more closely with the patient outcomes

In the TransATAC study the prognostic abilities of EPclin Risk Score and RS were compared directly. A total of 928 patients treated with 5 years endocrine therapy only were included. The primary endpoint was 10 year distant recurrence free survival.<sup>5</sup>



Distant recurrence free survival of ER+, HER2- patients within different risk groups from transATAC

EndoPredict demonstrates superior prognostic performance independent from cutoff values




EPclin Score and RS Prognostic Ability

\*The  $\chi^2$ -value is a standard statistic for prognostic power that is used to compare prognostic accuracy of different tests. The greater the  $\chi^2$ -value, the better is the prognostic power of a test. The  $\chi^2$ -value reflects the prognostic power of the continuous score independent from cutoff values.

\*\* RS non low = RS intermediate plus RS high.

## Outperforms other Signatures


The TransATAC study also compared the performance of four commercially available prognostic signatures for breast cancer distant recurrence (DR) in years 0-10 and in years 5-10. A total of 774 patients treated with 5 years endocrine therapy only were included.<sup>6</sup>




EndoPredict identified **most** node negative patients as low risk

Accuracy to Identify node negative low risk patients in years 0-10

EndoPredict identified most node positive patients with "true" low risk



Accuracy to Identify node positive low risk patients in years 0-10




EndoPredict was the most prognostic signature independent from cutoff values

\*\*\*The C-index is a standard statistic for prognostic power that is used to compare prognostic accuracy of different tests. The greater the C-Index, the better is the prognostic power of a test. The C-Index reflects the prognostic power of the continuous score independent from cutoff values.

EndoPredict (EPclin Score), Prosigna (ROR), Breast Cancer Index (BCI), Oncotype DX (RS)

## CE Marked as *in vitro* Diagnostic

EndoPredict meets the European regulatory requirements for safety, scientific validity, and clinical benefit. It can be used to improve the quality and safety of treatment of breast cancer patients in different disease stages.





## References:

1. Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. *Clin Cancer Res.* 2011; 17(18):6012-6020
2. Sestak I. et al.: Prediction of Distant Recurrence by EndoPredict in Patients with Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Received Adjuvant Endocrine Therapy plus Chemotherapy (ET+C) or Endocrine Therapy Alone (ET). *SABCS 2018*
3. Filipits M. et al.: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years. *SABCS 2018*
4. Dubsky P. et al.: EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. *Ann Oncol.* 2013; 24:640-647
5. Buus et al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. *J Natl Cancer Inst.* 2016 Jul 10; 108(11)
6. Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol.* 2018; 4(4):545-553
7. Dubsky P. et al.: The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. *BJC.* 2013; 109, 2959–2964
8. Martin M. et al.: Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. *BCR.* 2014; 16:R38
9. Jatoi I. et al. Breast cancer adjuvant therapy: time to consider its time-dependent effects. *J Clin Oncol.* 2011; 29(17):2301-2304.
10. Sestak I. et al.: Factors predicting late recurrence for estrogen receptor–positive breast cancer. *J Natl Cancer Inst.* 2013; 105(19):1504-1511
11. Müller B.M. et al.: Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. *J Clin Pathol.* 2012; 65:660-662
12. Denkert C. et al.: Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. *Virchows Arch.* 2012; 460:251-259
13. Kronenwett R. et al.: Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. *BMC Cancer.* 2012; 12:456
14. Muller B.M. et al.: The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. *PLoS ONE.* 2013; 8(6): e68252
15. Penault-Llorca et al.: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinicogenomic test on treatment decision making among patients with intermediate clinical risk. *SABCS 2016*
16. Ettl J. et al.: Decision Impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker UPA/PAI-1. *PLoS ONE.* 2017; 12(9): e0183917
17. Fallowfield L. et al.: Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing. *Psychooncology.* 2018 Apr; 27(4):1264-1269
18. Villarreal-Gfarca C. et al.: Change in therapeutic management after EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients. *SABCS 2018*
19. Dietel M. et al.: Der EndoPredict-Test hilft bei der Entscheidung endokrine Therapie +/- Zytostase. [The EndoPredict assay assists in decisionmaking about endocrine therapy +/- cytostasis] *Senologie– Zeitschrift für Mammadiagnostik und –therapie.* 2012;9:6-9
20. Blank P. et al.: Health economic analysis of guideline and gene expression signature-based risk stratification of distant recurrence in early breast cancer patients. Abstract - IMPAKT Meeting 2013
21. Brase J. et al.: From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis. *Microarrays.* 2013; 2, 243-264
22. Biermann J. et al.: Retrospective cost analysis of the EndoPredict test in patients with primary breast cancer in a German breast center. Annual Meeting of the German Association of Senology 2016
23. Senkus E. et al.: On behalf of the ESMO Guidelines Committee; Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015, 26 (Supplement 5): v8–v30, 2015
24. Harris L. et al.: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J. Clin. Oncol.* April 2016; 34, no. 10, 1134-1150.
25. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer Version 4.2018 – February 8, 2019
26. Poremba C. et al.: Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer. *Virchows Arch.* 2014; 465:409-17
27. Lehmann-Che et al.: First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. *Anticancer Res.* 2018; 38(5):2909-2914
28. Warf et al. Analytical validation of a 12-gene molecular test for the prediction of distant recurrence in breast cancer. *Future Sci.* 2017; OA. eISSN 2056-5623

# Our Expert Pathologist

## Assoc.Prof. Mirette Saad

MBBS (HONS) MD (HONS) MAACB FRCPA PHD

National Director of Molecular Genetics

Phone: 03 9538 6777

State: Victoria

Email: mirette.saad@clinicallylabs.com.au



Associate Professor Mirette Saad is an RCPA Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She obtained a PhD in Molecular Genetics from Melbourne University and Peter MacCallum Cancer Institute. A/P Saad chairs the RCPA Chemical Pathology Advisory Committee and is a member of the AACB and RCPA Genetic Advisory Committee.

## Ordering EndoPredict with Clinical Labs

### How to order

Please download the EndoPredict request form, which can be found at [clinicallylabs.com.au/endopredict](http://clinicallylabs.com.au/endopredict). Fill in patient details and clinical history, and select “EndoPredict”. Ensure that referring clinician details are complete, and if known, provide specimen details. If you would like a copy of the report to be sent to another clinician, please provide the necessary details.

### Specimens required

EndoPredict is performed on FFPE tumour tissue from biopsy or surgical specimens.

### Turnaround time

4–5 business days from the sample receipt date.

### Test cost

A partial Medicare rebate is available under item number 73306.

Patients are required to pay for EndoPredict prior to our laboratory conducting the test. Clinical Labs will contact your patient via SMS or phone call with payment instructions—please advise them to expect this communication in the days following the test request.

After making the payment online, Clinical Labs will send your patient a receipt, which they can use to claim the partial Medicare rebate directly from Medicare.

For current pricing and further information, please visit [clinicallylabs.com.au/endopredict](http://clinicallylabs.com.au/endopredict)

### Medicare Eligibility Criteria

Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin-fixed, paraffin-embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if:

- the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and
- the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and
- the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and
- the sample has no evidence of distal metastasis; and
- pre-testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics: (i) histopathological grade 2 or 3; (ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and
- the service is not administered for the purpose of altering treatment decisions

Applicable once per new primary breast cancer diagnosis for any particular patient